p.50 抽出テキスト

Circulation. 2017;136:e60–e122. DOI: 10.1161/CIR.0000000000000499 August 1, 2017 e109 CLINICAL STATEMENTS AND GUIDELINES

468.	 Biaggioni I, Freeman R, Mathias CJ, et al. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2015;65:101–7. 469.	 Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology. 1999;53:2151–7. 470.	 Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83:328–35. 471.	 Mathias CJ, Senard JM, Braune S, et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res. 2001;11:235–42. 472.	 Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson’s disease (NOH306A). J Parkinsons Dis. 2014;4:57–65. 473.	 Campbell IW, Ewing DJ, Clarke BF. 9-Alpha-fluorohydrocortisone in the treatment of postural hypotension in diabetic autonomic neuropathy. Diabetes. 1975;24:381–4. 474.	 Kochar MS, Itskovitz HD. Treatment of idiopathic orthostatic hypotension (Shy-Drager syndrome) with indomethacin. Lancet. 1978;1:1011–4. 475.	 Schoffer KL, Henderson RD, O’Maley K, et al. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson’s disease. Mov Disord. 2007;22:1543–9. 476.	 Vernikos J, Convertino VA. Advantages and disadvantages of fludrocortisone or saline load in preventing post-spaceflight orthostatic hypotension. Acta Astronaut. 1994;33:259–66. 477.	 Rowe PC, Calkins H, DeBusk K, et al. Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial. JAMA. 2001;285:52–9. 478.	 Shi SJ, South DA, Meck JV. Fludrocortisone does not prevent orthostatic hypotension in astronauts after spaceflight. Aviat Space Environ Med. 2004;75:235–9. 479.	 Gupta V, Lipsitz LA. Orthostatic hypotension in the elderly: diagnosis and treatment. Am J Med. 2007;120:841–7. 480.	 Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA. 2002;287:236–40. 481.	 Shibao C, Okamoto LE, Gamboa A, et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2010;56:847–51. 482.	 Singer W, Opfer-Gehrking TL, Nickander KK, et al. Acetylcholinesterase inhibition in patients with orthostatic intolerance. J Clin Neurophysiol. 2006;23:476–81. 483.	 Gales BJ, Gales MA. Pyridostigmine in the treatment of orthostatic intolerance. Ann Pharmacother. 2007;41:314–8. 484.	 Bordet R, Benhadjali J, Destée A, et al. Octreotide effects on orthostatic hypotension in patients with multiple system atrophy: a controlled study of acute administration. Clin Neuropharmacol. 1995;18:83–9. 485.	 Hoeldtke RD, Dworkin GE, Gaspar SR, et al. Effect of the somatostatin analogue SMS-201–995 on the adrenergic response to glucose ingestion in patients with postprandial hypotension. Am J Med. 1989;86:673–7. 486.	 Jarvis SS, Florian JP, Curren MJ, et al. A somatostatin analog improves tilt table tolerance by decreasing splanchnic vascular conductance. J Appl Physiol. 2012;112:1504–11. 487.	 Raimbach SJ, Cortelli P, Kooner JS, et al. Prevention of glucose-induced hypotension by the somatostatin analogue octreotide (SMS 201–995) in chronic autonomic failure: haemodynamic and hormonal changes. Clin Sci (Lond). 1989;77:623–8. 488.	 Craig GM. Clinical presentation of orthostatic hypotension in the elderly. Postgrad Med J. 1994;70:638–42. 489.	 McLachlan CY.L, Yi M, Ling A, et al. Adverse drug events are a major cause of acute medical admission. Intern Med J. 2014;44:633–8. 490.	 Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther. 2005;30:173–8. 491.	 Beckett NS, Connor M, Sadler JD, et al. Orthostatic fall in blood pressure in the very elderly hypertensive: results from the hypertension in the very elderly trial (HYVET) - pilot. J Hum Hypertens. 1999;13:839–40. 492.	 Fotherby MD, Potter JF. Orthostatic hypotension and anti-hypertensive therapy in the elderly. Postgrad Med J. 1994;70:878–81. 493.	 Räihä I, Luutonen S, Piha J, et al. Prevalence, predisposing factors,

and prognostic importance of postural hypotension. Arch Intern Med. 1995;155:930–5. 494.	 Perner A, De Backer D. Understanding hypovolaemia. Intensive Care

Med. 2014;40:613–5. 495.	 Journeay WS, Reardon FD, Jean-Gilles S, et al. Lower body positive and negative pressure alter thermal and hemodynamic responses after exercise. Aviat Space Environ Med. 2004;75:841–9. 496.	 Huang JJ, Desai C, Singh N, et al. Summer syncope syndrome redux. Am J Med. 2015;128:1140–3. 497.	 Lucas RAI, Ganio MS, Pearson J, et al. Sweat loss during heat stress contributes to subsequent reductions in lower-body negative pressure tolerance. Exp Physiol. 2013;98:473–80. 498.	 Jeukendrup AE, Currell K, Clarke J, et al. Effect of beverage glucose and sodium content on fluid delivery. Nutr Metab (Lond). 2009;6:9. 499.	 Maughan RJ, Leiper JB. Sodium intake and post-exercise rehydration in man. Eur J Appl Physiol Occup Physiol. 1995;71:311–9. 500.	 Merson SJ, Maughan RJ, Shirreffs SM. Rehydration with drinks differing in sodium concentration and recovery from moderate exercise-induced hypohydration in man. Eur J Appl Physiol. 2008;103:585–94. 501.	 Shirreffs SM, Taylor AJ, Leiper JB, et al. Post-exercise rehydration in man: effects of volume consumed and drink sodium content. Med Sci Sports Exerc. 1996;28:1260–71. 502.	 Atherly-John YC, Cunningham SJ, Crain EF. A randomized trial of oral vs intravenous rehydration in a pediatric emergency department. Arch Pediatr Adolesc Med. 2002;156:1240–3. 503.	 Greenleaf JE, Jackson CG, Geelen G, et al. Plasma volume expansion with oral fluids in hypohydrated men at rest and during exercise. Aviat Space Environ Med. 1998;69:837–44. 504.	 Kenefick RW, O’Moore KM, Mahood NV, et al. Rapid IV versus oral rehydration: responses to subsequent exercise heat stress. Med Sci Sports Exerc. 2006;38:2125–31. 505.	 Holtzhausen LM, Noakes TD. The prevalence and significance of postexercise (postural) hypotension in ultramarathon runners. Med Sci Sports Exerc. 1995;27:1595–601. 506.	 Evans GH, Shirreffs SM, Maughan RJ. Postexercise rehydration in man: the effects of osmolality and carbohydrate content of ingested drinks. Nutrition. 2009;25:905–13. 507.	 Blake AJ, Morgan K, Bendall MJ, et al. Falls by elderly people at home: prevalence and associated factors. Age Ageing. 1988;17:365–72. 508.	 Burke V, Beilin LJ, German R, et al. Postural fall in blood pressure in the elderly in relation to drug treatment and other lifestyle factors. Q J Med. 1992;84:583–91. 509.	 Jansen RW, Kelly-Gagnon MM, Lipsitz LA. Intraindividual reproducibility of postprandial and orthostatic blood pressure changes in older nursinghome patients: relationship with chronic use of cardiovascular medications. J Am Geriatr Soc. 1996;44:383–9. 510.	 Kamaruzzaman S, Watt H, Carson C, et al. The association between orthostatic hypotension and medication use in the British Women’s Heart and Health Study. Age Ageing. 2010;39:51–6. 511.	 Ooi WL, Barrett S, Hossain M, et al. Patterns of orthostatic blood pressure change and their clinical correlates in a frail, elderly population. JAMA. 1997;277:1299–304. 512.	 Jodaitis L, Vaillant F, Snacken M, et al. Orthostatic hypotension and associated conditions in geriatric inpatients. Acta Clin Belg. 2015;70: 251–8. 513.	 Panayiotou B, Saeed S, Fotherby M, et al. Antihypertensive therapy and orthostatic hemodynamic responses in acute stroke. Am J Hypertens. 2002;15:37–41. 514.	 Kanjwal K, Karabin B, Sheikh M, et al. Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience. Pacing Clin Electrophysiol. 2011;34:750–5. 515.	 Shibao C, Arzubiaga C, Roberts LJ, et al. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 2005;45:385–90. 516.	 Shibata S, Fu Q, Bivens TB, et al. Short-term exercise training improves the cardiovascular response to exercise in the postural orthostatic tachycardia syndrome. J Physiol. 2012;590:3495–505. 517.	 Fu Q, Vangundy TB, Shibata S, et al. Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. Hypertension. 2011;58:167–75. 518.	 Gaffney FA, Lane LB, Pettinger W, et al. Effects of long-term clonidine administration on the hemodynamic and neuroendocrine postural responses of patients with dysautonomia. Chest. 1983;83:436–8. 519.	 Green EA, Raj V, Shibao CA, et al. Effects of norepinephrine reup-

take inhibition on postural tachycardia syndrome. J Am Heart Assoc. 2013;2:e000395.

Downloaded from http://ahajournals.org by on October 7, 2026